Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Laboratory Services

 

FREE BLOG New HBI pipeline tool reveals long-held investments 

Nearly a third of all private equity-owned health care businesses in Europe have been held for at least five years, according to the new HBI Deals Pipeline tool. That suggests many private equity houses are struggling to sell on their investments.

Unilabs and Ribera Salud JV loses lab outsourcing contract

BR Salud, the Spanish JV owned by Unilabs and Ribera Salud, has lost its multi-million euro public contract to the country's fourth-largest lab group Analiza. It was worth, HBI estimates, 15-20% of Unilabs' Spain revenue.

Exclusive: Change at the top at Unilabs

Jos Lamers, 55, the man widely seen as the architect of modern-day Unilabs is moving away from a full-time role at the Pan-European lab and imaging platform, HBI can exclusively reveal. So what lies behind the move and who succeeds him as CEO?

Interview: Artem Sirazutdinov, Sistema and Medsi

By any measure, Sistema backed Russian healthcare network Medsi is doing rather well. Its most recent financial reports saw H2 revenue growth of over 40%, and the company continues to grow geographically. HBI caught up with Artem Sirazutdinov, chairman of the Medsi Board of Directors and a managing partner at Sistema, to find out more.

Fleury acquires Diagmax Group

Brazil's second-largest lab and imaging group Fleury has added six sites to its portfolio through the acquisition of local imaging group Diagmax Group.

France’s third largest lab group ‘for sale’

One of France's largest lab groups, Inovie, has appointed France-based international bank BNP Paribas to explore potential financing - but its complex shareholder structure and president's public objection to external investment leaves open questions about how any sale could work.

French labs strike over proposed 10% tariff cut

The majority of France's private lab groups have started a nine-day strike after the country's statutory insurer unveiled plans that could shrink reimbursement by 10% over the next three years.

Find Us